Brokerages Expect Integra Lifesciences Holdings Corp (NASDAQ:IART) Will Announce Earnings of $0.65 Per Share

Share on StockTwits

Analysts predict that Integra Lifesciences Holdings Corp (NASDAQ:IART) will report earnings of $0.65 per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Integra Lifesciences’ earnings. The highest EPS estimate is $0.66 and the lowest is $0.63. Integra Lifesciences reported earnings per share of $0.60 in the same quarter last year, which would suggest a positive year-over-year growth rate of 8.3%. The company is expected to issue its next earnings report on Wednesday, July 24th.

On average, analysts expect that Integra Lifesciences will report full-year earnings of $2.70 per share for the current financial year, with EPS estimates ranging from $2.68 to $2.72. For the next financial year, analysts anticipate that the firm will report earnings of $3.00 per share, with EPS estimates ranging from $2.98 to $3.04. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Integra Lifesciences.

Integra Lifesciences (NASDAQ:IART) last issued its earnings results on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.61 by $0.04. Integra Lifesciences had a return on equity of 15.60% and a net margin of 5.60%. The firm had revenue of $359.69 million for the quarter, compared to analysts’ expectations of $361.12 million. During the same quarter last year, the business earned $0.58 earnings per share. The company’s revenue was up .7% compared to the same quarter last year.

Several research firms have recently weighed in on IART. Cantor Fitzgerald reiterated a “hold” rating and set a $50.00 price objective on shares of Integra Lifesciences in a report on Thursday, February 21st. BidaskClub cut Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Oppenheimer cut their price objective on Integra Lifesciences from $70.00 to $65.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. ValuEngine cut Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Thursday, April 18th. Finally, Zacks Investment Research upgraded Integra Lifesciences from a “hold” rating to a “buy” rating and set a $59.00 price objective on the stock in a report on Thursday, May 9th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $58.00.

Shares of NASDAQ:IART traded up $0.28 during trading on Monday, hitting $51.16. 148,449 shares of the company’s stock traded hands, compared to its average volume of 467,274. Integra Lifesciences has a 52 week low of $42.14 and a 52 week high of $67.50. The company has a current ratio of 2.86, a quick ratio of 1.86 and a debt-to-equity ratio of 0.95. The firm has a market cap of $4.37 billion, a P/E ratio of 21.14, a price-to-earnings-growth ratio of 1.47 and a beta of 0.97. The firm has a 50-day simple moving average of $50.12.

In other Integra Lifesciences news, Director Christian S. Schade sold 15,658 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $51.56, for a total value of $807,326.48. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 4.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IART. Municipal Employees Retirement System of Michigan acquired a new position in shares of Integra Lifesciences during the 4th quarter worth approximately $766,000. Campbell Newman Asset Management Inc. increased its position in shares of Integra Lifesciences by 2.4% during the 1st quarter. Campbell Newman Asset Management Inc. now owns 9,278 shares of the life sciences company’s stock worth $517,000 after purchasing an additional 218 shares during the last quarter. Stevens Capital Management LP acquired a new position in shares of Integra Lifesciences during the 1st quarter worth approximately $1,413,000. JPMorgan Chase & Co. increased its position in shares of Integra Lifesciences by 104.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,064 shares of the life sciences company’s stock worth $18,251,000 after purchasing an additional 141,368 shares during the last quarter. Finally, Blueshift Asset Management LLC acquired a new position in shares of Integra Lifesciences during the 4th quarter worth approximately $230,000. Hedge funds and other institutional investors own 82.27% of the company’s stock.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Story: Technical Analysis

Get a free copy of the Zacks research report on Integra Lifesciences (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

William I. Jacobs Sells 600 Shares of Global Payments Inc  Stock
William I. Jacobs Sells 600 Shares of Global Payments Inc Stock
Stewart Butterfield Sells 2,500 Shares of Slack  Stock
Stewart Butterfield Sells 2,500 Shares of Slack Stock
Alice Lindsay Caulder Sells 501 Shares of World Acceptance Corp.  Stock
Alice Lindsay Caulder Sells 501 Shares of World Acceptance Corp. Stock
Insider Buying: ALS Ltd  Insider Buys 14,983 Shares of Stock
Insider Buying: ALS Ltd Insider Buys 14,983 Shares of Stock
Opko Health Inc.  CEO Purchases $106,000.00 in Stock
Opko Health Inc. CEO Purchases $106,000.00 in Stock
Robert Langer Sells 7,500 Shares of Rubius Therapeutics Inc  Stock
Robert Langer Sells 7,500 Shares of Rubius Therapeutics Inc Stock


© 2006-2019 Ticker Report